These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36219116)

  • 1. Myocardial Activity at
    Wang L; Wang Y; Wang J; Xiao M; Xi XY; Chen BX; Su Y; Zhang Y; Xie B; Dong Z; Zhao S; Yang MF
    Radiology; 2023 Feb; 306(2):e221052. PubMed ID: 36219116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional significance of myocardial activity at
    Zhang Y; Dong Z; Wang L; Wang YL; Chen BX; Su Y; Zhao S; Yang MF
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):110-122. PubMed ID: 37642705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
    Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
    [No Abstract]   [Full Text] [Related]  

  • 4. Feasibility of
    Wang X; Guo Y; Gao Y; Ren C; Huang Z; Liu B; Li X; Chang L; Shen K; Ding H; Zhang H; Tian Z; Hacker M; Zhang S; Wang Y; Li J; Li X; Huo L
    JACC Cardiovasc Imaging; 2022 Nov; 15(11):1960-1970. PubMed ID: 36357138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of
    Wang L; Tang G; Hu K; Liu X; Zhou W; Li H; Huang S; Han Y; Chen L; Zhong J; Wu H
    Radiology; 2022 Apr; 303(1):191-199. PubMed ID: 34981976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy.
    Wu G; Liu J; Wang S; Yu S; Zhang C; Wang D; Zhang M; Yang Y; Kang L; Zhao S; Hui R; Zou Y; Wang J; Song L
    Heart; 2021 Oct; 107(19):1576-1583. PubMed ID: 33361398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy.
    Ismail TF; Jabbour A; Gulati A; Mallorie A; Raza S; Cowling TE; Das B; Khwaja J; Alpendurada FD; Wage R; Roughton M; McKenna WJ; Moon JC; Varnava A; Shakespeare C; Cowie MR; Cook SA; Elliott P; O'Hanlon R; Pennell DJ; Prasad SK
    Heart; 2014 Dec; 100(23):1851-8. PubMed ID: 24966307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
    Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
    J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy.
    Norrish G; Ding T; Field E; Cervi E; Ziółkowska L; Olivotto I; Khraiche D; Limongelli G; Anastasakis A; Weintraub R; Biagini E; Ragni L; Prendiville T; Duignan S; McLeod K; Ilina M; Fernández A; Marrone C; Bökenkamp R; Baban A; Kubus P; Daubeney PEF; Sarquella-Brugada G; Cesar S; Klaassen S; Ojala TH; Bhole V; Medrano C; Uzun O; Brown E; Gran F; Sinagra G; Castro FJ; Stuart G; Vignati G; Yamazawa H; Barriales-Villa R; Garcia-Guereta L; Adwani S; Linter K; Bharucha T; Garcia-Pavia P; Siles A; Rasmussen TB; Calcagnino M; Jones CB; De Wilde H; Kubo T; Felice T; Popoiu A; Mogensen J; Mathur S; Centeno F; Reinhardt Z; Schouvey S; O'Mahony C; Omar RZ; Elliott PM; Kaski JP
    Circ Arrhythm Electrophysiol; 2022 May; 15(5):e010075. PubMed ID: 35491873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging.
    Xie B; Wang J; Xi XY; Guo X; Chen BX; Li L; Hua C; Zhao S; Su P; Chen M; Yang MF
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2786-2797. PubMed ID: 34984503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered regional myocardial velocities by tissue phase mapping and feature tracking in pediatric patients with hypertrophic cardiomyopathy.
    Li A; Ruh A; Berhane H; Robinson JD; Markl M; Rigsby CK
    Pediatr Radiol; 2020 Feb; 50(2):168-179. PubMed ID: 31659403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of adverse left ventricular remodeling on sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Vriesendorp PA; Schinkel AF; de Groot NM; van Domburg RT; Ten Cate FJ; Michels M
    Clin Cardiol; 2014 Aug; 37(8):493-8. PubMed ID: 25044226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Comparison of
    Lan L; Zhang S; Xu T; Liu H; Wang W; Feng Y; Wang L; Chen Y; Qiu L
    Radiology; 2022 Sep; 304(3):648-657. PubMed ID: 35579524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
    Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy.
    Liu J; Zhao S; Yu S; Wu G; Wang D; Liu L; Song J; Zhu Y; Kang L; Wang J; Song L
    Radiology; 2022 Feb; 302(2):298-306. PubMed ID: 34726536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Level of Troponin but Not N-Terminal Probrain Natriuretic Peptide Is Associated with Increased Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy Calculated According to the ESC Guidelines 2014.
    Rajtar-Salwa R; Hładij R; Dimitrow PP
    Dis Markers; 2017; 2017():9417908. PubMed ID: 29358842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the association between serum uric acid level andthe predicted risk score of sudden cardiac death in five years in patients with hypertrophic cardiomyopathy.
    Özyılmaz S; Satılmışoğlu MH; Gül M; Uyarel H; Serdar OA
    Turk Kardiyol Dern Ars; 2018 Mar; 46(2):111-120. PubMed ID: 29512627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
    Maron MS; Rowin EJ; Wessler BS; Mooney PJ; Fatima A; Patel P; Koethe BC; Romashko M; Link MS; Maron BJ
    JAMA Cardiol; 2019 Jul; 4(7):644-657. PubMed ID: 31116360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.